BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
October 30 2018 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, today
announced that it will report its third quarter 2018 financial and
operating results on Thursday, November 8th, 2018, following the
close of the U.S. financial markets. BioTime management will also
host a conference call and webcast on Thursday, November 8th, 2018,
at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its
third quarter 2018 financial results and to provide a business
update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and should request the “BioTime Inc.
Call”. A live webcast of the conference call will be available
online in the Investors section of BioTime’s website. A replay of
the webcast will be available on BioTime’s website for 30 days and
a telephone replay will be available through November 15th,
2018, by dialing (855) 859-2056 from the U.S. and Canada and (404)
537-3406 from elsewhere outside the U.S. and entering conference ID
number 8658619.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE
American: OCX), and a private company, AgeX Therapeutics,
Inc.
Regarding the dividend distribution of AgeX Therapeutics, Inc.
that we have previously announced, and with respect to certain
index funds in Israel, we have been informed that a third party has
committed to purchase any and all shares of AgeX from all index
funds in Israel at a price of $2.80 per share and up to a maximum
dollar amount of $2.5 million.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company on
Twitter, LinkedIn, Facebook, YouTube, and Google+. To
receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert
list: http://news.biotime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181030005287/en/
BioTime Inc. IRIoana C. Hone,
510-871-4188(ir@biotimeinc.com)orSolebury Trout IRGitanjali
Jain Ogawa, 646-378-2949(Gogawa@troutgroup.com)
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024